Harvard Medical School professor to speak at Moffitt’s 8th Annual Ted Couch Cancer Research Lectureship

January 26, 2006

Tampa, FL — The H. Lee Moffitt Cancer Center & Research Institute presents the 8th Annual Ted Couch Cancer Research Lectureship featuring Judah Folkman, M.D., Fri., Feb. 3, 4 p.m. in the Ted and Marty Couch Auditorium in the Vincent A. Stabile Research Building, 12902 Magnolia Dr., Tampa. A reception will follow the presentation.

The lecture, titled “Antiangiogenic Therapy of Cancer and Other Diseases” will be presented by Folkman, a professor of cell biology at Harvard Medical School and director of the vascular biology program in the department of surgery at Children’s Hospital Boston.

Please RSVP by Jan. 31 by calling 1-888-MOFFITT (1-888-663-3488).

Folkman is the founder of the field of angiogenesis (growth of new blood vessels) research, his hypothesis (1971) that solid tumors are angiogenesis-dependent initiated studies of angiogenesis in tumor biology and in disciplines as diverse as developmental biology, ophthalmology and dermatology. Folkman’s laboratory reported the first purified angiogenesis molecule and inhibitor, and it proposed the idea of angiogenic disease. All of these discoveries have been translated into numerous clinical trials. Because of his research angiogenesis inhibitors are now approved in the U.S. and in 28 other countries. Largely because of his research, the possibility of antiangiogenic therapy is now on a firm scientific foundation, not only in treatment of cancer, but also in the treatment of many non-neoplastic diseases.

In 1990, he was elected to the National Academy of Sciences, and he is a member of the American Academy of Arts and Sciences, the American Philosophical Society and the Institute of Medicine. From 1967 he served as surgeon-in-chief at Children’s Hospital Boston for 14 years.

In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in recognition of its excellence in research and contributions to clinical trials, prevention and cancer control. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in the U.S. News & World Report as one of the top cancer hospitals in America. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.